A novel anti-diabetic drug that lowers blood glucose levels by acting on the kidneys, instead of the liver or the pancreas, has been approved by the USFDA.
The drug, Invokana (Canagliflozin), works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels in diabetics. Its safety and effectiveness were evaluated in nine clinical trials involving over 10,285 patients with type 2 diabetes.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/usfda-okays-safer-diabetes-drug-which-acts-kidneys
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/indian-express-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/diabetes
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/diseases
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-effects
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
